Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer
NCT04436393 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 109
Last updated 2022-06-22
Summary
The purpose of this study is to observe the routine clinical care of patients who have been diagnosed with breast cancer and have undergone Guardant360 testing.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Guardant360 test
tumor cfDNA testing
Sponsors & Collaborators
-
Guardant Health, Inc.
lead INDUSTRY
Principal Investigators
-
Victoria M Raymond, M.S. · Guardant Health, Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-07-02
- Primary Completion
- 2022-03-17
- Completion
- 2022-03-17
Countries
- United States
Study Locations
More Related Trials
-
Long Term Follow-Up in Patients With Stage 0-IIIC Breast Cancer
NCT04661982 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluation of Beauty Care Before Chemotherapy in Women With Breast Cancer
NCT01459003 ·Status: COMPLETED ·Phase: PHASE3
-
Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI
NCT02587663 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy
NCT02610621 ·Status: WITHDRAWN ·Phase: PHASE2
-
Technology and Health Communication in Improving Health Outcomes in Patients Scheduled for Mammography
NCT04290585 ·Status: COMPLETED ·Phase: NA
-
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
NCT06780176 ·Status: RECRUITING
-
Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast Cancer
NCT00080860 ·Status: COMPLETED ·Phase: NA
-
Identification of New Prognostic Markers for Breast Cancer.
NCT03436069 ·Status: RECRUITING
-
Living Well With Advanced Breast Cancer
NCT07227038 ·Status: RECRUITING
-
Study of Sentinel Lymph Node Assessment Following Previous Surgical Biopsy for Early Breast Cancer
NCT00293865 ·Status: COMPLETED ·Phase: NA
-
Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy
NCT05866458 ·Status: RECRUITING
-
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer
NCT06833502 ·Status: RECRUITING ·Phase: PHASE2
-
Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients
NCT01446185 ·Status: COMPLETED ·Phase: NA
-
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer
NCT03255577 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for Breast Cancer
NCT05850637 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Patients With HER2-Positive Metastatic Breast Cancer
NCT00105456 ·Status: COMPLETED
-
Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients
NCT05837533 ·Status: COMPLETED ·Phase: NA
-
Study of Metabolites Markers in Adjuvant Breast Cancer
NCT03367208 ·Status: COMPLETED
-
Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient
NCT03007641 ·Status: COMPLETED ·Phase: NA
-
Omission of Radiation in Patients With Her-2 Positive Breast Cancer
NCT03460067 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Sentinel Node Biopsy Before and/or After Neoadjuvant Chemotherapy in Breast Cancer
NCT02031042 ·Status: COMPLETED
-
Elevate! : An Elderly Breast Cancer Cohort Study
NCT03818087 ·Status: ACTIVE_NOT_RECRUITING
-
Magnetic Seed Localisation of Breast Cancers
NCT02635737 ·Status: COMPLETED ·Phase: NA
-
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928 ·Status: RECRUITING ·Phase: NA
-
Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability
NCT06382818 ·Status: RECRUITING ·Phase: NA